Hormone Therapy May Skew Mammograms
Abnormal Mammograms Found in Some Women Taking Estrogen and Progestin, Study Shows
Feb. 25, 2008 -- Women who take combined hormone therapy, even for a short time, are at significantly increased risk of having suspicious mammograms and undergoing breast biopsies as a result, new research shows.
New findings from the large, randomized trial that first raised warnings about hormone therapy use and breast cancer suggest that treatment with estrogen and progestin decreases the effectiveness of mammograms and breast biopsies for detecting breast cancer.
In the follow-up of about 8,500 participants in the Women's Health Initiative (WHI) trial, more than one in 10 women who took the hormone combination for five years had suspicious mammograms that they would not have had otherwise, and one in 25 women had avoidable breast biopsies, researchers say.
WHI researcher Rowan T. Chlebowski, MD, PhD, of Harbor-UCLA Medical Center, says women considering combined hormone therapy to treat hot flashes and other symptoms of menopause should definitely be told of the risk.
"The actual increase in (breast cancer) risk associated with taking even combined hormone therapy for this period of time is very small," he tells WebMD. "But a user's risk for having an abnormal mammogram or undergoing a breast biopsy that she may not need is substantial. This is something women considering hormone therapy need to be aware of."
Combined Hormone Therapy Revisited
Chlebowski says the WHI trial offered a unique opportunity to study the impact of hormone therapy on breast cancer screening and detection because all the women who took the combined hormones stopped at the same time, when the study was stopped early because of concerns about heart attack and breast cancer risk.
Millions of other women taking hormones for a host of reasons also stopped taking estrogen plus progestin when the WHI findings were made public.
The therapy is now recommended only for the relief of menopause-related hot flashes and other symptoms, and women are advised to use it in the smallest effective dosage for the shortest possible time.
Of the 16,608 original participants in the trial, 199 women who took the hormones and 150 women who did not take them developed invasive breast cancer over five years.
Compared with women who did not take the hormones, women taking them had a 4% greater risk of having an abnormal mammogram after one year of hormone use and an 11% greater risk after five years of use.
To put it another way, roughly one in three women who took the hormones (35%) had abnormal mammograms, compared with slightly less than one in four (23%) placebo-treated women.
Breast biopsies were also more common in women taking hormones, with 10% having biopsies compared with 6% of women in the placebo arm of the study.
Biopsies led to a diagnosis of breast cancer in 15% of women taking estrogen and progestin and just under 20% of women who did not take hormones.
The updated WHI findings appear in the Feb. 25 issue of the Archives of Internal Medicine.
"This shouldn't scare anybody away from taking combined hormone therapy if they need it," Chlebowski says. "But women on the fence may decide that the extra risk of having a mammogram that needs follow-up isn't worth it."